AstraZeneca Annual Report and Form 20-F Information 2008

Notes to the Financial Statements (Company)

1 Fixed asset investments

		Investments in subsidiaries
	Shares  (restated)  $m	Loans  $m	Total  (restated)  $m
Cost and net book value at 1 January 2008, as previously reported	15,286	15,069	30,355
Prior year adjustment – UITF 44	724	–	724
Restated at beginning of year	16,010	15,069	31,079
Additions	14,700	787	15,487
Disposals	(14,700)	–	(14,700)
Transfer to current assets	–	(2,045)	(2,045)
Capital contribution – UITF 44	178	–	178
Exchange	–	(372)	(372)
Amortisation	–	8	8
Repayment of loan	–	(2,908)	(2,908)
Cost and net book value at 31 December 2008	16,188	10,539	26,727

During 2007, the Company formed a new subsidiary, AstraZeneca Intermediate Holdings Limited. On 11 March 2008, the Company sold its wholly owned subsidiary, AstraZeneca UK Limited, to AstraZeneca Intermediate Holdings Limited, in consideration for the issue of further shares in AstraZeneca Intermediate Holdings Limited.

During the year, the Company has adopted the requirements of UITF Abstract 44 ‘Group and Treasury Share Transactions’ and restated prior year comparatives.

Back to the top